Ranbaxy launches generic anti-ulcer drug
Ranbaxy has launched generic versions of Astrazeneca’s anti-ulcer drug Prilosec 40 mg in the US.
By ET Bureau |
NEW DELHI: Ranbaxy has launched generic versions of Astrazeneca���s anti-ulcer drug Prilosec 40 mg in the US. Following a settlement in April, Astrazeneca made Ranbaxy the authorized generics partner, which means that the Indian company can sell its generic drugs for 180 days before Prilosec���s patent expires.
However, the US-based company Watson Pharma, being the first generic company to successfully challenge Prilosec���s patent, will also have exclusive marketing rights during the 180 day period.
According to IMS figures, Prilosec 40 mg has annual sales of $204 million in the US, a Ranbaxy release said. Ranbaxy���s shares at the BSE closed at Rs 494.20, up 2.6% from Friday���s close.
However, the US-based company Watson Pharma, being the first generic company to successfully challenge Prilosec���s patent, will also have exclusive marketing rights during the 180 day period.
According to IMS figures, Prilosec 40 mg has annual sales of $204 million in the US, a Ranbaxy release said. Ranbaxy���s shares at the BSE closed at Rs 494.20, up 2.6% from Friday���s close.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
